Biotech Reviews & More


BioSig Technologies, Inc. BSGM

We began tracking many stocks with coronavirus synergies back in the late winter and early spring this year, as the global threat was still in the earlier stages of emergence. Our first alert on BSGM was on April 7th, and the stock would go on to run from under $4 to more than $12,

In the last few weeks, BSGM has finally begun to come down off of those highs, and we are now interesting in tracking it more closely for a potential bottom bounce. We’ll be looking out for the stock to establish support, and possibly make another significant run in coming weeks.
_____

iBio, Inc. IBIO

Speaking of coronavirus related stocks that have done well, IBIO was among those that we have been tracking since word of the pandemic began to spread widely, and we have seen a very nice move from it as well.

Following our most recent mention on March 17th, the stock saw  a low of .76, and to finish off last week it hit a new high of 2.69. That’s a 254% increase, and a perfect example of the kind of impetus that the virus has provided to a lot of these mid-sized biotechs.


Ideanomics, Inc. IDEX

We took notice of an interesting situation with IDEX currently transpiring. Last week, the stock tumbled on word of a possible class action suit currently being investigated. Today, it’s bouncing back in the premarket after the company announced the delivery of more than $3M in Chinese EV orders.

We’ll be interested to track its progress out of the gate as we kick off a fresh trading week today, without any notable earnings reporters on the calendar.


Extended Watchlist:
ITRM, LVXI, MYRY, PVDG, DECN, BHTG,

Winning Options Review & More

Adobe, Inc. ADBE – Review 

On Friday morning, we reminded readers to stick with our preexisting options idea for ADBE. which was gearing up big in the premarket to make some serious gains. Our targets were the ADBE $397.50-$405 Calls.

In addition to making multi-bag moves overnight, those options ideas did in fact deliver on the Friday intraday gains that we essentially guaranteed.

ADBE $397.50-$405 Calls
$397.50: 2.19-11.08 (+405%)
$400: 1.53-9.23 (+503%)
$402.50: 1.35-6.72 (+398%)
$405: .68-5.01 (+637%)


Other Updates

We had also signaled some contracts in a couple of other chains as well on Friday morning, and in both cases, we witnessed some decent intraday gains. They didn’t go parabolic, but still posted the following respectable moves on the day:

BITA 06/19 $15-17.50 Calls
$15:
1.20-1.65 (+38%)
$17.50: .35-.50 (+43%)

PLAY Weekly $15.50-16.50 Calls
$397.50:
 1.31-2.20 (+68%)
$400: 1.11-1.90 (+71%)
$402.50: .95-1.60 (+68%)
_____

Fresh Options Idea:
SPY 06/15 $300-298 Puts*

*Trading these puts is tantamount to trading weekly contracts on a Friday. Do not attempt to do so unless you are an advanced trader with access to disposable funds. 


Extended Watchlist:
FORW, DTGI, BLLB, HMNY, ZHUD, BSGM 

MAR Puts, BSGM Updates

Marriot International, Inc. MAR – Update

The markets took a late dive yesterday afternoon, and as they plunged, it helped our bearish idea on MAR realize some nice new gains. We were just reporting on the MAR Weekly $86.50-85 Puts in yesterday’s report, with what were only nominal gains at the time. Today the figures are looking far more impressive.

Even after the company’s CEO somewhat brashly called MAR stock ‘a bottom’, traders did not agree as it took a considerable hit and headed lower. That produced the following opportunities in our targeted puts;

MAR Weekly $86.50-85 Puts
$86.50:
2.80-7.00 (+150%)
$86:2.70-6.60 (+144%)
$85.50: 2.20-5.02 (+128%)
$85: 2.13-5.97 (+180%)
______

Fresh Options Ideas: 
ALC Weekly $55-57.50 Calls
PGTI Weekly $10 Calls
CYBR Weekly $107-104 Puts


BioSig Technologies, Inc. BSGM

We have been tracking BSGM pretty closely this spring, and the stock has put together an incredible performance. Subsequent to our alert of this play roughly 5 weeks ago on April 7th, it registered a low of 3.45/share. The company has been doing trials for potential coronavirus treatments with the drugs Merimepodib and Remdesivir.

After stacking gains on top of gains and essentially going up continuously with very few daily exceptions, BSGM arrived at a new high of 12.43 yesterday. That represents an increase of 260% in just over a month’s time!

We will certainly continue to track BSGM’s progress and keep our ears to the track for any further developments in the company’s quest for a viable COVID-19 treatment.


Extended Watchlist:
JCP, AGNC, HOG, HTBX, RTTR